Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13991878 | 0.95 | CYP1A2 (0.48) | ALDH1A1EPHX2CYP1A2GAAPLA2G4A | |
| SCHEMBL13991912 | 0.87 | GAA (0.46) | ALDH1A1EPHX2CYP1A2PLA2G2AGAA | |
| SCHEMBL4781039 | 0.82 | PLA2G4A (0.67) | ALDH1A1EPHX2PLA2G2AGAAPLA2G4A | |
| SCHEMBL10081657 | 0.81 | ALDH1A1 (0.50) | ALDH1A1EPHX2CYP1A2NAMPTGAA | |
| SCHEMBL11789446 | 0.81 | KMT2A (0.61) | ALDH1A1EPHX2CYP1A2NAMPTGAA | |
| SCHEMBL13286569 | 0.80 | TSHR (0.52) | ALDH1A1EPHX2PLA2G2APLA2G4A | |
| SCHEMBL10080728 | 0.80 | EPHX2 (0.50) | ALDH1A1EPHX2CYP1A2NAMPTGAA | |
| SCHEMBL13991913 | 0.80 | EPHX2 (0.49) | ALDH1A1EPHX2PLA2G2AGAAPLA2G4A | |
| SCHEMBL11783978 | 0.79 | KDM4E (0.59) | ALDH1A1EPHX2CYP1A2NAMPTGAA | |
| SCHEMBL13991921 | 0.78 | TSHR (0.55) | ALDH1A1EPHX2CYP1A2PLA2G2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | PLA2G4A, PLA2G4B, PLA2G2A | ALDH1A1 3131/4885EPHX2 140/4885CYP1A2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.